Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D1.227 - Nanobody-based anti-FcεRI antibodies for therapeutic targeting of the IgE-FcεRI complex
D1.228 - Mitochondrial Epigenetic Programming: A Unifying Mechanism Linking Environmental Stress, Epithelial Barrier Dysfunction, and Allergy
D1.229 - Real-life observational study on allergen-specific Immunotherapy with double-polymerized allergoids (Modigoid Cup a1) in patients allergic to Cupressus Arizonica pollen
D1.218 - Effects of butyrylated high amylose maize starch (HAMSB) as an adjuvant for oral immunotherapy
D1.219 - Efficacy and Safety of 300 IR Liquid Sublingual Immunotherapy in Allergic Asthma: A Systematic Review and Meta-analysis of Randomised Controlled Trials
D1.221 - Identification of IgE epitopes of major ragweed pollen allergens (Amb a 1 and Amb a 11)
D1.222 - Production of Bet v 1-specific IgG antibodies in mice immunized with the recombinant vaccine ABP-Vax
D1.223 - TNFR2 regulates early PD-L1/PD-L2 induction and Th1-associated cytokine responses during the early events of Allergen-Specific Immunotherapy (AIT) in a preclinical model
D1.224 - Rational Design of a T-Cell Epitope-Based Chimeric Allergen from Dermatophagoides pteronyssinus Toward Precision Immunotherapy
D1.225 - Long-term adherence to seasonal allergen immunotherapy: a 3-year (22/23-24/25) retrospective study on 174 patients
D1.226 - Allergen Immunotherapy Preferences by Patient in Some Arabic countries: The CHOICE-Middle East Study
D1.230 - Efficacy and Safety of Hymenoptera Venom Immunotherapy in a Patient with Systemic Mastocytosis
D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma
D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report
D1.108 - Optimization of phenotyping in severe T2-bronchial asthma
D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy
D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients
D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study
D1.114 - Efficacy of Radical Endoscopic Surgery Combined with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps Complicated with Bronchial Asthma: A Real-World research
D1.115 - Real World Assessment of Uncontrolled Severe Asthma in Canada - A Multi-Site Qualitative Survey of Type 2 Inflammatory Biomarkers and Clinical Outcomes
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download